

Editorial: The role of immune cells in the progression of autoimmune diseases affecting the CNS

Czeslawa Kowal, Jelka Pohar, Flora Zavala

▶ To cite this version:

Czeslawa Kowal, Jelka Pohar, Flora Zavala. Editorial: The role of immune cells in the progression of autoimmune diseases affecting the CNS. Frontiers in Immunology, 2021, 12, $10.3389/\mathrm{fimmu.}2022.1078396$. hal-04086699

HAL Id: hal-04086699

https://hal.science/hal-04086699

Submitted on 2 May 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



OPEN ACCESS

EDITED AND REVIEWED BY Makoto Inoue, University of Illinois at Urbana-Champaign, United States

*CORRESPONDENCE Czesława Kowal CKowal@northwell.edu Jelka Pohar jelka.pohar@nib.si Flora Zavala flora.zavala@inserm.fr

[†]These authors have contributed equally to this work

SPECIALTY SECTION

This article was submitted to Autoimmune and Autoinflammatory Disorders: Autoimmune Disorders, a section of the journal Frontiers in Immunology

RECEIVED 24 October 2022 ACCEPTED 27 October 2022 PUBLISHED 09 November 2022

CITATION

Kowal C, Pohar J and Zavala F (2022) Editorial: The role of immune cells in the progression of autoimmune diseases affecting the CNS. Front. Immunol. 13:1078396. doi: 10.3389/fimmu.2022.1078396

COPYRIGHT

© 2022 Kowal, Pohar and Zavala. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: The role of immune cells in the progression of autoimmune diseases affecting the CNS

Czeslawa Kowal 1,2*†, Jelka Pohar 3*† and Flora Zavala 4*†

¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, United States, ²Molecular Medicine at Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States, ³Immunology and Cellular Immunotherapy, Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, Ljubljana, Slovenia, ⁴Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, Paris, France

KEYWORDS

CNS pathophysiology, dendritic cells, mucosal-associated invariant T cells, STAT3, Th17 cells, PP2C δ , supramolecular organizing centers (SMOCs), neutrophil extracellular traps

Editorial on the Research Topic:

The role of immune cells in the progression of autoimmune diseases affecting the CNS

Insights into the dynamics of immune responses in immune-privileged tissues such as the central nervous system (CNS) are critical to understanding the etiology of autoimmune diseases. Essential in this field is understanding the ways immune cells access and traffic across different types of the blood-brain barrier (BBB), and how the therapeutics alter these processes (see excellent review by Mapunda et al.). The current Research Topic brought into attention a diverse panel of original research papers and two reviews on the immune cells involved in CNS pathophysiology, including dendritic cells (DC), mucosal-associated invariant T (MAIT) cells, neutrophils, and pathogenic Th17 cells, as well as a different aspects of that pathophysiology, including molecular signaling pathways (PP2Cδ) and the role of signaling complexes, known as supramolecular organizing centers (SMOCs), therapeutic interventions (STAT3-specific nanobody, treatment of rheumatoid meningitis with intravenous immunoglobulin - IVIg), possible new forms of autoantigens (neutrophil extracellular traps (NETs) in neuropsychiatric systemic lupus erythematosus - NPSLE), and assessment of correlation between inflammatory markers and severity of autoimmune encephalitis (AE).

It is becoming increasingly clear that metabolism is intrinsically linked to the function of immune cells and their interaction with other cells (1). DCs represent major contributors to the immune response by presenting antigen and secreting diverse cytokines. Lv et al. demonstrate that ablation of the phosphatase PP2C δ in DCs unleashed their activation leading to abnormal Th1/Th17 differentiation and

Kowal et al. 10.3389/fimmu.2022.1078396

exacerbated EAE pathology. PP2Cδ loss led to de-repression of the methyltransferase NSD2, thereby boosting the Rictor/mTORC2 pathway inducing major metabolic changes in DCs such as elevated mitochondrial oxidative phosphorylation and aerobic glycolysis. By inducing ATP-citrate lyase (ACLY), it also stimulated histone acetylation, facilitating the expression of genes characterizing hyperactivated DCs. PP2Cδ therefore exerts a key role in DC activation and function *via* the Rictor/mTORC2/ACLY pathway that controls immune homeostasis *via* metabolic and epigenetic regulations.

MAIT cells are highly conserved unconventional T cells activated by riboflavin-derived bacterial and yeast antigens presented by MHC-related protein 1 (MR1). MAIT cells are of explicit interest in multiple sclerosis (MS) (2), a T-cell-driven, autoimmune inflammatory neurological disease, due to their abundance, intrinsic effector-memory phenotype and capability to produce proinflammatory cytokines. Gargano et al. report an evidence of gut dysbiosis of MS patients compared with healthy donors (HD) by metagenomics and metataxonomic analysis of cultivable faecal samples collected from both groups. MAIT cells derived from MS patients show higher level of activation and proliferation in response to fungal isolates overrepresented in MS group (C. albicans and S. cerevisiae), and an increased proinflammatory cytokine production by activated innate immune cells. Importantly, MAIT cells containing proinflammatory cytokines were detected in the active brain lesions of MS patients.

Low density neutrophils (LDNs) were correlated with disease activity in systemic lupus erythematosus (SLE). Their contribution to pathology in SLE is attributed to their capacity to produce type I IFNs and to spontaneously form NETs containing autoantigens and proinflammatory proteins. In the review Sim et al. assess the role of LDNs in NPSLE; their proinflammatory function and the participation in the opening of the BBB, hence allowing the anti-neuronal pathogenic antibodies entering the brain parenchyma. The pathogenicity of these antibodies in NPSLE and the role of matrix metalloproteinase-9 and neutrophil gelatinase-associated lipocalin in BBB disruption are also evaluated. Finally, NETs as a source of autoantigens, especially oxidized mitochondrial DNA, enabling to sustain or to initiate autoimmune response, as well as possible therapeutic interventions are discussed.

Infiltration of pathogenic T-cells is a hallmark of several autoimmune diseases including uveitis and multiple sclerosis. Mbanefo et al. present a transcription factor STAT3 that plays an important role in the biology of Th1 and particularly Th17 T cells. Although STAT3 is an intracellular protein that is not easily targeted, the authors used the camelid nanobody. In the animal model of experimental autoimmune uveitis (EAU), which targets retina – another immune-privileged tissue, the STAT3-specific antibody was able to efficiently penetrate the blood retina barrier and suppress the differentiation, proliferation, and cytokine release of Th17 cells, leading to

EAU amelioration. Authors provide a perspective for the development of future therapeutics to specifically inhibit pathogenic cells, particularly in immune-privileged organs such as the CNS.

Rheumatoid meningitis represents a rare complication of rheumatoid arthritis in the CNS. Zhang et al. report on a case diagnosed on the basis of rheumatoid factor, anti-cyclic citrullinated peptide antibody and IL-6 positivity in the CSF and the serum together with the unexpected presence of anti-NMDAR Abs in the CSF. Brain MRI confirmed hyperintensity of frontal and parietal lobes. IVIg was effective to alleviate clinical symptoms and lesions and restore normal levels of biochemical indicators except for persisting anti-NMDAR Abs.

Autoimmune encephalitis is another inflammatory disease that targets cells of the CNS and causes complex clinical manifestations such as motor dysfunction and psychiatric disorders. Different scoring systems such as the modified Rankin Scale (mRS) or the Clinical Assessment Scale for Autoimmune Encephalitis (CASE) are combined to accurately assess the severity of the disease (3). In addition, inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) are becoming increasingly popular to help clinicians monitor disease progression, prognosis, and response to treatment. Liu et al. for the first time demonstrated the positive association between MLR and the severity of AE.

The increasing incidence of neurodegenerative diseases such as Alzheimer's is a growing public health problem and a burden on society. Misfolded proteins and aggregates cause direct neurotoxicity and contribute to the production of inflammatory mediators *via* activation of pattern recognition receptors, leading to neuroinflammation and, in later stages, BBB damage and infiltration of peripheral immune cells (Chee and Solito). This neuroinflammation is propagated through SMOCs, comprised of ligands, sensors, adaptors, and effectors that form multiprotein complexes such as myddosomes, inflammasomes, and necrosomes. Sušjan-Leite et al. provide a comprehensive overview of SMOCs involved in neuroinflammation and their role in the development of neurodegenerative and neuroinflammatory diseases by linking innate and adoptive immunity.

In conclusion, we hope this Research Topic will stimulate new studies testing and expanding therapeutic potentials reported here, dissecting molecular pathways even further to spare immune protection and to provide base for new clinical trials.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Kowal et al. 10.3389/fimmu.2022.1078396

Funding

This work was supported by the NIH grant 1P01 AI073693-06, Research Fund of The National Institute of Biology (10ICIGEN) and Slovenian Research Agency (P1-0245, J3-3084).

Acknowledgments

We would like to thank all authors for their contributions to this Research Topic. We also thank all the reviewers for their comprehensive and timely evaluation of the submitted manuscripts.

References

- 1. Jung J, Zeng H, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol (2019) 21(1):85–93. doi: 10.1038/s41556-018-0217-x
- 2. Ammitzbøll C, von Essen MR, Chow HH, McWilliam O, Holm Hansen R, Sellebjerg F. MAIT cell subtypes in multiple sclerosis. *J Neuroimmunol* (2020) 339 (November 2019):577117. doi: 10.1016/j.jneuroim.2019.577117

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

3. Lim J-A, Lee S-T, Moon J, Jun J-S, Kim T-J, Shin Y-W, et al. Development of the clinical assessment scale in autoimmune encephalitis. *Ann Neurol* (2019) 85 (3):352–8. doi: 10.1002/ana.25421